These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17035667)

  • 1. SAR by NMR: putting the pieces together.
    Hajduk PJ
    Mol Interv; 2006 Oct; 6(5):266-72. PubMed ID: 17035667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of NMR-derived fragment leads in drug design.
    Huth JR; Sun C; Sauer DR; Hajduk PJ
    Methods Enzymol; 2005; 394():549-71. PubMed ID: 15808237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand specificity in fragment-based drug design.
    Barelier S; Pons J; Gehring K; Lancelin JM; Krimm I
    J Med Chem; 2010 Jul; 53(14):5256-66. PubMed ID: 20575554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment-based deconstruction of Bcl-xL inhibitors.
    Barelier S; Pons J; Marcillat O; Lancelin JM; Krimm I
    J Med Chem; 2010 Mar; 53(6):2577-88. PubMed ID: 20192224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR.
    Petros AM; Huth JR; Oost T; Park CM; Ding H; Wang X; Zhang H; Nimmer P; Mendoza R; Sun C; Mack J; Walter K; Dorwin S; Gramling E; Ladror U; Rosenberg SH; Elmore SW; Fesik SW; Hajduk PJ
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6587-91. PubMed ID: 20870405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design in silico, synthesis and binding evaluation of a carbohydrate-based scaffold for structurally novel inhibitors of matrix metalloproteinases.
    Fragai M; Nativi C; Richichi B; Venturi C
    Chembiochem; 2005 Aug; 6(8):1345-9. PubMed ID: 15977273
    [No Abstract]   [Full Text] [Related]  

  • 7. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.
    Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH
    J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SAR by ILOEs: an NMR-based approach to reverse chemical genetics.
    Becattini B; Pellecchia M
    Chemistry; 2006 Mar; 12(10):2658-62. PubMed ID: 16121405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors.
    Porter J; Payne A; de Candole B; Ford D; Hutchinson B; Trevitt G; Turner J; Edwards C; Watkins C; Whitcombe I; Davis J; Stubberfield C
    Bioorg Med Chem Lett; 2009 Jan; 19(1):230-3. PubMed ID: 19027294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragment-based synthesis and SAR of modified FKBP ligands: influence of different linking on binding affinity.
    Röhrig CH; Loch C; Guan JY; Siegal G; Overhand M
    ChemMedChem; 2007 Jul; 2(7):1054-70. PubMed ID: 17541991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design.
    Hohwy M; Spadola L; Lundquist B; Hawtin P; Dahmén J; Groth-Clausen I; Nilsson E; Persdotter S; von Wachenfeldt K; Folmer RH; Edman K
    J Med Chem; 2008 Apr; 51(7):2178-86. PubMed ID: 18341273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Design, synthesis and activity evaluation of novel matrix metalloproteinases inhibitors based on the structure of enzyme].
    Jia H; Guo YS; Ge YY; Wen H; Yang J; Yang XY; Du GH; Yang GZ
    Yao Xue Xue Bao; 2007 Dec; 42(12):1271-81. PubMed ID: 18338640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring experimental sources of multiple protein conformations in structure-based drug design.
    Damm KL; Carlson HA
    J Am Chem Soc; 2007 Jul; 129(26):8225-35. PubMed ID: 17555316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.
    Huth JR; Park C; Petros AM; Kunzer AR; Wendt MD; Wang X; Lynch CL; Mack JC; Swift KM; Judge RA; Chen J; Richardson PL; Jin S; Tahir SK; Matayoshi ED; Dorwin SA; Ladror US; Severin JM; Walter KA; Bartley DM; Fesik SW; Elmore SW; Hajduk PJ
    Chem Biol Drug Des; 2007 Jul; 70(1):1-12. PubMed ID: 17630989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid protein-ligand costructures using chemical shift perturbations.
    Stark J; Powers R
    J Am Chem Soc; 2008 Jan; 130(2):535-45. PubMed ID: 18088118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment-based drug design: how big is too big?
    Hajduk PJ
    J Med Chem; 2006 Nov; 49(24):6972-6. PubMed ID: 17125250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragment-based lead discovery: a chemical update.
    Erlanson DA
    Curr Opin Biotechnol; 2006 Dec; 17(6):643-52. PubMed ID: 17084612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress in small-molecule inhibitors of Bcl-2 family proteins].
    Tang Y; Zhang DY; Wu XM
    Yao Xue Xue Bao; 2008 Jul; 43(7):669-77. PubMed ID: 18819468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.